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Objectives. To investigate the role of kinin in preconditioning 
against infarction, the present study assessed the effect of capto- 
pril, a kininase II inhibitor, on preconditioning and arterial 
plasma kinin levels. 
Eac&gmund. Recent studies suggest a possible contribution of 
kinin to preconditioning against infarction. However, its role and 
the site of kinin production remain uncharacterized. 
Methods. Six groups of rabbits (n = 6 to 13) underwent 30-min 
coronary occlusion and 3-h reperfusion. The infarct size and area 
at risk were determined by tetramlium staining and fluorescent 
particles, respectively. Arterial blood was sampled under baseline 
conditions, before the 30.min ischemia and after repefisioo for 
ranioimnmnoassay of the kinin level. 
ResuILF. Infarct size expressed as a percentage of area at risk 
(%lS/AR) was 42.9 + 2.m (mean f SEM) in the control group, 
34.5 f 33% in the group preconditioned with 2 min of 
ischemia/S min of reperlusion and 41.7 f 5.1% in the group given 
captopril (1 mg/kg body weight) alone before the 30-min ischemia. 
These %IS/AR values were not significantly diferent between the 
three groups. However, a combination of captopril and subse- 
- 
Myocardial tolerance to 5chemic injury is markedly enhanced 
by exposing the myocaraium to a brief episode of &hernia 
followed by a period of reperfusion. This phenomenon, called 
precondirioning, has been widely confirmed in various animal 
models (1,2), and its presence is implicated in the human heart 
by circumstantial evidence, including attenuation of ST seg- 
ment elevation after repetitive coronary balloon inflation 
during percutaneous transluminal coronary angioplasty (3), 
and deceleration of ischemia-induced adenosine triphosphate 
depletion in the myocardium after preconditioning (4). Al- 
though the mediator in the preconditioning-like phenomenon 
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quent preconditioning with 2 min of ischemia markedly limited 
%IS/AR to 21.2 f 2.4%. This potentiation of 2 min of preeondi- 
tioning by captopril was not observed when 2 &kg body weight of 
Hoe 140, a specific bradykinin 8, receptor antagonist, was admin- 
istered before preconditioning (IISIAR = 41.2 f 5.7%), whereas 
Hoe 146 alone did not modify infarct size (%&/AR = 38.5 + 
5.1%). Arterial plasma kinin levels were comparable between the 
control rabbits, the group given captopril alone and the group that 
received captoprll plus 2 min of preconditioning at baseline (38 f 
1.0,6.3 f 1.9 and 5.2 f 1.7 pg/ml, respectively), and there was no 
significant change in kiain levels after the captopril iwtion or 
the combination of captopril plus 2 min of preconditioning. 
Conclusions. The present results indicate that captopril is 
capable of potentiating preconditioning without increasing the 
arterial klnln level and that the beneflclal erect of captopril can be 
inhibited by Hoe 140. These findings support the hypothesis that 
kinin produced locally in the heart during pmconditioning may 
contribute to the cardiopmtective mechanism through bradykinin 
receptor activation. 
(J Am Cail Cdiol1996;28:1616-22) 
in human hearts is still poorly understood, the key role of an 
adenosine (probably A,!AJ receptor has been demonstrated 
in the mechanism of preconditioning against infarction in most 
of the animal species examined to date (1,2,5-7). However, 
there are a number of other subst;lnces that are thought tC be 
reieased during preconditioning ischemia/reperfusion that may 
contribute to the cardioprotectian agail:;t infarction. One such 
substance is kinin, which is known to be produced in a severely 
ischemic myocardium (8,9), but its physiologic significance is 
still not clear. Recently, Wall et al. (10) reported that infa:cl 
size limitation by preconditioning in the rabbit was blocked by 
a bradykinin B, receptor antagonist, Hoe 140 (ll), and was 
mimicked by kinin administration. These results suggest that 
kinin may also be an important mediator, as well as adenoFne, 
in the mechanism of preconditioning. 
However;it has not been demonstrated whether k-an is 
indeed prdduced in the myocardium during a brief period of 
preconditioning &hernia and contributes to cardioprotection. 
To gain insi&t into’ this issue, the present :‘~tIy.a~~ssed the 
effect of captopril, a kininase II (i.e., angiotensin-converting 
enzyme [ACE]) inhibitor, on the infarct size limiting effect of 
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preconditioning in a rabbit model of myocardial infarction. If 
production of kinin during preconditioning is indeed a crucial 
mechanism, inhibition of kinin degradation by captopril (12) 
can ,be expected to enhance the cardioprotective effect of 
preconditioning, and that effect should be abolished by a kinin 
antagonist. To easily detect the porsibie potentiation of the 
cardioprotection by captopril, the duration of preconditioning 
ischemia was selected as 2 min, which has been shown (7) to 
very modestly protect the heart against infarction. We also 
assessed the effect of captopril on arterial plasma kinin levels 
to test whether captopril modifies preconditioning through 
increasing circulating plasma kinin levels. 
Methods 
Surgical preparation. The study conformed to the Guide- 
lines of Sapporo Medical University on Research Animal Use. 
The surgical preparation in the present study was essentially 
the same as tha! in our previous studies (1,6,7). Male albino 
rabbits (Japanese White) weighing 1.8 to 2.9 kg were intrave- 
nously anesthetized by pentobarhital (30 mgkg body weight), 
and additional anesthesia was given during the experiment as 
needed. A tracheostomy was performed, and mechanical ven- 
tilation was provided by a Halvard respirator (model 683) 
using room air and oxygen supplement. Tidal volume, respira- 
tory rate and oxygen supplement were adjusted to maintain 
arterial blood gas within the normal physiologic range. A 
fluid-filled catheter was inserted into the carotid artery and 
connected to a Nihon-Kohden SCK-580 transducer to monitor 
biood pressure. Another catheter was placed in the jugular 
vein for infusing drugs. Electrocardiographic electrodes were 
placed on the chest wall, corresponding to CC5 leads. The 
heart was exposed by left lateral thoracotomy. and 4-O silk 
thread was passed around a marginal branch of the left 
circumflex coronary artery with a tapered needle. The ends of 
the silk thread were passed through a small vinyl &be to make 
a snare. The rabbits were subjected to pretreatment (see 
Experimental protocol), and the coronary artery was occluded 
by the coronary snare. Myocardial ischemia was confirmed by 
regional cyanosis and ST segment change on the electrocar- 
diogram. After 30 min of coronary occlusion. the coronary 
artery was reperfused by releasing the snare. Reperfusion was 
confirmed by the restoration of color to the iyhemic region. 
Three hours after reperfusion; the rabbit underwent hepa- 
rinizatioo with 2.ooO U of heparin and was killed by a 
pentobarbital overdose. The heart was quickly removed and 
p-d for postmortem analysis. 
Posbnortem adysls. The heart was mounted on a Langen- 
dorlf apparatus and perfnsed with salii to wash out the 
MlKi ET AL. 
CAPTOPRIL POTENTIATES PRECONDITIONING 
1617 
: : 
remaining blood. The coronary branch was reoccluded and 
fluorescent particles (3 to 30 pm in dia?eter, Duke Sc$ntific 
Co.) were infused into the perfusate to negativkly mark the 
area,at risk (the territory of the occluded &ionary artery). The 
heart was then froien and sectioned inro Lbmm transverse 
slices. The heart slices w&e incubated .tiith 1% triphenyl 
tetrazolium in 100 mmoliliter sodium phosphate buffer 
(pH 7.4) for 20 min to visualize infarcts (13). The slices were 
mounted on a glass press and compressed to exactly 2 mm. A 
clear acetate sheet was overlaid on the glass press, and then the 
infarcts (i.e., regions unstained by tetrazolium) and areas at 
risk (i.e., regions deficient of fluorescent particles) were traced 
on the acetate sheet under room light and under ultraviolet 
light, respectively. The traces were enlarged by 20% using a 
Xerox copy machine. The areas of the infarct and region at risk 
were measured by PIAS II, a computer-assisted image analysis 
system (PIAS Co., Osaka, Japan), and each volume was 
calculated by multiplying the area by the thickness of the heart 
slice. 
Extdmental protocol. After hemodynamic variables had 
been stabilized for 10 min, baseline hemodynamic variables 
were measured, and the rabbits then undetwent pretreatment 
and 30 min of coronary occlusionl3 h of reperfusion. In the first 
series of experiments, 40 rabbits were randomly divided into 
four groups (n = 10 for each group): Control group, 2’PC 
group, Cap group and CapR’PC group. The Control group was 
subjected to the 30 min of &hernia without any pretreatment. 
In the 2’PC group, the heart was preconditioned with 2 min of 
ischemia and 5 min of reperfusion before the 30-min coronary 
occlusion. The Cap group received an intravenous injection of 
1 mg/kg of captopril22 min before the coronary occlusion. The 
CapLZ’PC group received the same dose of captopril and was 
preconditioned with 2 min of ixhemid min of reperfusion. 
Because the mean of the size of area at risk in the Cap/2’PC 
group was slightly smaller than those. in the other groups 
(although the differences were not statistically significant), an 
additional five rabbits were added to this group. In the Control. 
Cap and Cap/2’PC groups arterial blood for kinin assay was 
sampled immediately after the baseline hemodynamic mea- 
surements; the second sample was taken 2 min before the 
30-min coronary artery occlusion (20 min after captopril 
injection in the Cap and CapFPC groups); the third sample 
was taken 5 min after reperfusion. The blood sample was 
drawn from the arterial line directly into a syringe containing a 
mixture of aprotinine, polybrene, soybean trypsin inhibitor, 
phenanthroline and EDTA to inhibit both kinin production 
and degradation (14). 
In the second series of experiments. 14 rabbits were ran- 
domly assigned to the Hoe (n = 7) and Cap/HoeL?‘PC groups 
(n. = 7). In addition. for every two rabbits assigned to these 
groups, #we, prepared one contemporary control; thus, three 
rabbits were subjected to no pretreatment, and four were 
preconditioned with 2 min of ischemia. We did not completely 
randomize the 21 rabbits into the four groups in this series 
becausetheControland2’PCgroupsinthefirstseriaofthe 
experiment had already provided good infarct size data for 
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Table 1. Summary of Kemodyamic Variables 
Group n Basclinc Afwr TX 
___. 
khcmia Rcpcrfukn 5’ Rqxrfusicrn I fill’ 
HR (hcats’min) 
13 2.56 5 I I 2in 2 11 262 z I I 26X Y IO 25s ? 7 Contrql 
2’PC 13 272 2. I I 273? II 275 :: II m ‘c Y 2.57 f 12 
cap 0 283 i_ 7 287 T s 374 i s xi1 : 9 2x2 f 13 
Cap.2’PC 13 -- ‘6’ ?Y . 5 266 Y : 26.7 z 7 759 -. - . 7 263 I II 
Hoc 6 25.3 2 I? 250 Y 1-l 36 i I4 2% z 9 271 .‘I 19 
Cap~Hoc:3’PC 7 h, Y’. I, - + 1.3 3s f s 2X’) 5 x x7 .: IO 3Y3 z 13 
MAP (mm Hg) 
Control I3 s7 lr 4 SY I 4 $4 2 s 6’) I 5:’ SY 24’ 
?‘PC 13 SW c .; X6 2 3 ss I 3 77 2 3” 6: + 4‘ 
Cap Y x3 i 2 7-J x 2 71 5 3 58 z 3* 53 z 4% 
Cap 2’PC I3 91) z 3 80 f 4 76 t 3” f-36 z 1’ 63 + 4* 
HW 6 x11 + 6 Xl 2 5 86 2 5 74 I 8 57 ? x* 
Cap;Hoc:2’PC 7 ,s6 c 5 78 Lc 4 79 t 4’ h9?3- 64 f: .I* 
RPPilNl 
Control 13 2.3 t 211 251 x I4 ----- 751 * 7, 220 i 2-l IX5 ). 14‘ 
2’PC 13 272 2 15 266 2 1s 264I 1-l 237 : 13 203 z 1 I * 
Cap Y 77’ m-- + IO 258 2 9 ‘19 z 9 ml + 13‘ 198 2 16’ 
Cap,‘Z’PC 13 270t II 253 2 11 24nk I4 210 -c 13’ 21’ + is= 
Hoc 6 235 ? 37 236 + 23 x1 -t 2.5 219 + 2x 191 z 27 
CapiHoeZPC 7 2xn k 23 262 + 14 2h3 + 17 237 2 I5 7-1 0 w + - ,5 
- 
? < 0.05 versus hascline values in each study group (see Enpcrimenlal protocol for cxpianatiw of study groups). Dal2 pruscnted are mean valur 2 SD. After TX = 
1 min bL%re corrmary wxlurion; HR = heart rak: lschemia = 3 min after coronary occlusion: MAP = mean arterial prcssurc: Repcrfurion 5’ and 180’ = 5 and 1x0 min 
after repe~.ksion. rcspeckly: RPP = rare-pressure product. 
nonpreconditionld and preconditioned hearts. In the Hoe 
group, 2 ccg/kg of t!oe 140 was injected intravenously 12 min 
before coronary occlu-ion. The CaplHoelZ’PC group received 
captopril and Hoe 140 ,.efore preconditioning with 2 min of 
ischemiaB min of reperfusim. In this group, the timing of the 
injection and the dose of capi?pril and Hoe 140 were the same 
as that in the Cap and the ;qoe group, respectively. The 
2-&kg dose of Hoe 140 was selerZd because half of this dose 
has been shown (10) to abolish preLqnditioning with 5 min of 
ischemia. We also confirmed in pilot cvperiments that 2 Fg/kg 
of Hoe 140 almost completely blocked ;qr at least 60 min the 
hypotensive response to an injection of 10~ nglkg of bradykinin 
into the leti atrium, which was a decrease in Qod pressure of 
-30 mm Hg in untreated rabbits. 
Exclusion criteria. We excluded rabbits if th;y developed 
ventricular fibrillation that did not terminate spor$aneously 
within 1 min or if diastolic blood pressure after recovel:r from 
ventricular fibrillation was ~40 mm Hg. Our previous study (6) 
showed that hypotension below this level may cause an exten- 
sion of infarction during the reperfusion period in the present 
model. No pharmacologic agents were used for defibrillation 
or to maintain blood pressure. 
PIasma kinio assay. After plasma was separated by cen- 
trifugation of the blood sample at 4”C, kinin was extracted with 
ethanol and assayed by a highly sensitive radioimmunoassay 
method, as previously reported (14). : 
Chemicals. Captopril was purchased from Sigma Co., and 
Hoe 140 was provided by Hoechst AG, Germany. 
Statistical analysis. Hemodynamic variables and alter- 
ations in plasma kinin levels were compared between groups by 
two-way repeated measures analysis of variance with a multi- 
variate linear model (SigmaStat, Jandel Scientific) to correct 
for the differing group sizes (15). Differences in infarct size 
data between groups Nere tested by one-way ANOVA. When 
the overall difference was significant, a multiple comparison 
was performed by the Student-Newman-Keuls post hoc test. 
Results are expressed as mean value 5 SEM. 
Results 
Because baseline hemodynamic variables, heart weight and 
the size of area at risk were comparable between the study 
groups in the first series of experiments and those in the second 
series, the results of both series were combined and presented 
together as follows. 
Exclusion of rabbits. According to the exclusion criteria, 
we excluded five rabbits from the following analysis; two 
rabbits in the Capl2’PC groups, one in the 2’PC group, one in 
the Cap group and one in the Hoe group. The two rabbits in 
the Cap/2’PC were not defibrillated, and the other three failed 
to maintain diastolic blood pressure >4O mm Hg after recovery 
from ventricular fibrillation. 
Hemodynamic variables. Hemodynamic variables in the six 
study groups are summarized in Table 1. Heart rate, mean 
blood pressure and rate-pressure product were comparable in 
all groups at baseline. Two-way repeated measures ANOVA 
indicated no significant changes in heart rate but a significant 
time-related reduction in mean blood pressure and rate- 
pressure product during the experiments. No group-related 
effects were detected for either mean blood pressure or 
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Table 2. Summary of Infarct Size Data 
Group’ n 
- 
COlllrOl 13 
2’PC 1: 
Cap 9 
Cap’Z’PC 13 
Hoe 6 
Cap/Hne!?PC 7 
Hcan Weight 
@I 
6.3 z 11.3 
6.8 ‘c 0.3 
i.c + n.3 
6.4 2 ‘I.? I- 
6 .- ’ -: Il.4 
6.6 _C (I.3 
Arca ;II Risk 
(cm’) 
0.7)i e !).I!+ 
n.7’) : 0.w 
0.7s z o.ux 
I).fl5 I 0.06 
II.: ? 0.1 I 
0.73 2 0.11 
‘See Experimental protocol for explanation of stud!, group>. tp i 0.05 ~crsus Control group. Dats prcunrcd ;+re mean value z SD. 
rate-pressure product (p = NS). These results suggest that the 
effects of preconditioning, captopril and Hoe 140, and a 
combination of these, did not significantly Jlter the time course 
of these hemodynamic variables in the present rabbit model of 
infarction. 
Infaret size data. Infarct size data are summarized in Table 
2. Heart weight and size of the area at risk were similar in all 
groups. Infarct size as a percentage of the area at risk 
(%IS/AR) was 42.9 + 2.9% in the Control group and 41.7 2 
5.1% in the Cap group (p = NS). The %lS/AR was smaller in 
the 2’PC group (34.5 ? 3.3%) than the Control group. 
although the difference did not reach statistical significance. In 
contrast, %IS/AR in the CapEPC group was 21.2 2 2.4%, 
which was significantly smaller than that in the Control and 
Cap groups. Before three rabbits were added (see Experimen- 
tal protocol) to this group to make the size of area at risk more 
comparable (thus, the area at risk was 0.60 -)_ 0.07 cm3. n = 
10). %IS/AR was 20.2 2 3.0% (p < 0.05 vs. Control group). 
These findings indicate that pretreatment with captopril po- 
tentiated the infarct size-limiting effect of 2 min of precotidiu 
tioning. In the Hoe group and Cap/HoeEPC group, %IS/AR 
was 41.2 ? 5.7% and 38.5 2 5.1%, respectively, both of which 
were similar to the control infarct size, and these values were 
significantly larger than the %IS/AR in the Capl2’PC group. 
Because %IS/AR is an index that can be influenced by the 
risk area size in the rabbit model of infarction (16), the effect 
of captopril on preconditioning was also assessed in light of the 
infarct size-risk area size relation. As shown in Figure 1, the 
regression line between the infarct size and risk area size 
shifted slightly toward smaller infarcts in the 2’PC group, but 
this shift was not statistically sign&ant (panel A). Although 
captopril Jone did not shift the regression line between infarct 
size and risk area size, the regression line in the CapL!‘PC 
group was significantly less steep than that of the Control 
group (Fig. 1, panel B). Hoe 140 alone did not shift the 
regression line, but this agent blocked the dovvnward shift of 
the regression line by eaptopril plus 2 mm of preconditioning 
(Fig. 1, panel C). This analysis also shows the significant infarct 
size limitation by the combination ofcaptopril and 2 min of 
preconditioning, which was inhiiitable by Hoe 140. 
PIasma kInIn Ieds. Plasma kinin levels at baseline’ were 
3.8 + 1.0, 63 t 1.9 and 5.2 +- 1.7 in the Control, Cap and 
Figure 1. 5catterplots of the relation hetwecn infarct size and size of 
area at risk. Paw1 A. Control group versus ?‘PC group. The wgfrsrioa 
line of the “PC group (y = 0.27~ + 0.06. r = 0.36) was not different 
from that of the Control group (y = 0.55x -0.09. r = 0.87). Panel 8. 
Control group versus Cap and Cap/2’PC groups. The rrgmsion liw of 
the CaplZ’PC group (y = 0.20x + 0.01. r = 0.70) was significantly less 
steep than that of the Control group. whereas there was no significant 
difference between the regression line of the Cap group (y = 0.76x - 
0.24. r = 0.91) and that of the Control group. Panel C, Control group 
versus Hoe group and Cap/Hoe/I!‘PC group. The qressian lines of 
the Hoe (y = 0.65x - 0.16, r = 0.85) and CaplHoel2’PC groups (y = 
0.61x - 0.13. r = 0.94) did not differ from that of the Control group. 
See Experimental protocol for explanation of study soups. 
0.8- 
0 Comrol 
0.6’ l 2’K 
0.4. 
0.6’ l cap 
A C~PC 
0.4’ 
Area at Risk (cm3 ) 
o-- -17 
Baselint: After TX Reperfu~ion 
Figure 2. Time courw of change in plasma kinin Icwls in arterial 
hid. Basclins plasma kinin levels were comparable in the Control 
(open circles). Cap (solid circlrrl and Cap/?PC groups (triangles). 
and there was no significant alteration in the plasma kinin levels before 
and after the cor,mary occlusion in these three groups. After TX = 
immediately before cnronaq occlusion: Reperfusion = 5 min after 
corona9 reperfusion. See Experimental protocol for explanation nf 
study groups. 
Cap/2’PC groups, respectively (p = NS). In all three groupa 
there was no significant alteration in arterial plasma kinin 
I<.:els during the time course of prsischemic and reperfusiun 
periods, as shown by Figure 2. 
Discussion 
In the present study, captopril potentiated the infarct 
size-limiting effect of preconditioning with 2 min of ischemia. 
and this cardioprotec!ive effect was abolished by Hoe 140, a 
specific bradykinin B, receptor antagonist. However, plasma 
kinin levels in arterial blood were not changed b; iile admin- 
istration of captopril or its combination with preconditioning. 
These results support the hypothesis that generation of kinin in 
the heart during preconditioning contributes, through Bz re- 
ceptor activation, to infarct size limitation by preconditioning. 
Kinin production in heart. A limitation of the present 
study is the absence of direct data of kinin production in the 
ischemic myocardium. It is not technically possible to collect 
venous blood from the territory of the left marginal artery in 
the rabbit heart, and blood sampling from the coronary sinus 
does not allow accurate assessment of kinin metabolism in the 
ischemic region of the heart. Accordingly, we took an approach 
that excluded involvement of systemic circulating kinin in 
preconditioning. Hoe 140, a specific B, receptor antagonist 
(1 I), complett ly abolished the cardioprotection of captopril 
and precondhioning, suggesting a, contribution of ‘the !$ 
receptor. In cc~ntrast, the dose of captopril used in the present 
study did not change arterial kinin levels with or wiihout the 
combination of preconditioning (Fig. 2), although different 
doses of ACE inhibitors have been shown (17,lH) to increase 
circulating plasma kinin levels in humans. However, the finding 
that arterial kinin ievqls were not elesatcd by captopril dots 
not n&cssafily contradict the success&l inhibition of kiniriase 
II hv captopril in the heart because the effect of kininasc I! 
inhibition on kinip levels depends on the rate of kinin produc- 
tion. which. presumably, was high in the ischemic myocardium. 
Several earlix sturlie , demonstrated that kinit production in 
the myocardium is -,ccelerated h) ischemia both in vivo (8.9) 
and in vitro (19.2’;). Baumgarten et al. (19) showed thal the 
kinin relcase after IS min of coronar?; occlusion was enhanced 
I-,y pretreatment with an ACE inhibitor. ramiprilat. in isolated 
rat hearts. In contrast. the s!ight blood pressure decrease after 
captopril (Table I) can he explained by the suppression of 
angiotrnsin II production by inhibiting ACE. Taken together, 
the present findings suggest that the kinin that contributed to 
the cardioprotection of preconditioning was produced locally 
in the rabbit heart. 
Effect of captopril in nonpreconditioned hearts. In con- 
trast to the marked cardioprotectivr effect of a combination of 
captopril and preconditioning, captopril alone failed to limit 
infarct size This result is consistent with the observations in 
our prclious study (21) as well in others (22-24). However. 
there are also reports of infarct size limitation by the same 
agents (25-28). and the reason for the discrepancy remains 
unclear. 
Pntentiatioo of preconditioning: captopril versus nucleu- 
side transport. Like captopril in the present study, nucleoside 
transport inhibitors were shown to potentiate preconditioning 
with 2 min of ischemia against infarction. In our previous 
studies (7.2’)). pretreatment of rabbits with dipyridamole. 
dilazcp and R75231 before preconditioning with 2 min of 
ischemia limited infarct to -30% of the infarct size in the 
untreated control rabbits, whereas any of the nucleoside 
transport inhibitors alone failed to modify infarct size. Further- 
more, the effect of nucleoside transport inhibitors was inhib- 
ited by H-phenyl-theophylline (7), suggesting an adenosine- 
mediated mechanism. In contrast, the captopril-induced 
cardioprotection of 2 min of preconditioning was abolished by 
Hoe 140, which is a specific antagonist of the B, receptor and 
has no known antagonistic action on an adenosine receptor. 
The extent of infarct size limitation by the combination of 
dipyridamole or captopril with 2 min of preconditioning was 
comparable to that by preconditioning with 5 min of ischemia. 
A possible explanation of these findings may be that accumu- 
lation of either kinin or adenosine in the cardiac interstitium 
up to a certain threshold could trigger the cardioprotective’ 
mechanism, although the levels of both substances are below 
the threshold during 2 min of preconditioning without capto- 
pril or nucleo$de transport inhibitors. 
Mechanism of precunditiuniag downstream to B, rercptor 
activation. The present study cannot specify the cardioprotec- 
tive mechanism downstream to activation of the B, receptor. 
The & receptor is coupled with phospholipases AZ and C through 
G. proteins (13,30), and stimulation of this receptor leads to the 
production of two important vasoactive substances-prostacyclin 
and nitric oxide. However, neither cyclooxygenase inhibitors (i.e., 
aspirin and meclofenamate) (31) nor the nitric ox& synthase 
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inhibitor, nitro-L-arginine methyl ester (32.33) attenuated infarct 
siielimitition by preconditioning in the rabbit model of infarc- 
tion. ln~rontrast. p$ymyxin B. a blocker of protein kinase C. 
reportedly abolished.infarct size limitation by pretreatment with 
kinin in a study by Goto et al. (32). Although Goto et al. (32) did 
not try other protein kinase C inhibitors on kinin-induced cardio- 
protection in that particular study. they demonstrated that poly- 
myxin B. staurosporinc (34) and cheletythrine ;35) are capable of 
bkx+tg preconditioning against infarction in the in vitro and in 
vivo rabbit model of infarction. Furthermore. a recent study using 
isolated cardiac myocytes shmed that B, receptor stimulation 
caused significant inositol triphosphatr production (36) suggest- 
ing that simultaneously generated diacylglycerol could activate 
protein kinase C. Taken together, this circumstantial evidence 
suggests that protein kinase C activation may play a key role in 
cardioprotection after I+, receptor activation. 
WC thank Ryhei Soraw.~ PhU and Jamcc 51. Dowry. PhD for a*\isIing with 
~tali+lical anal!w3. 
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